May 052011

Rubboli et al summarize the (weak) evidence and current guidelines. General avoidance of drug-eluting stents in those with need of long-term warfarin is still the party-line recommendation, with triple therapy (warfarin, aspirin, clopidogrel) for those who receive a DES due to a strong indication. While TT is clearly superior for high risk patients (e.g., mechanical valve), the net benefit is less clear for those with either a high HAS-BLED bleeding risk score or a low CHADS2 stroke risk score of 0-1. Flawed evidence suggests that most of the increased bleeding on TT (over and above the bleeding risk from warfarin with one antiplatelet agent) is "minor." CHEST 2011;139:981-987.

Liked this post? Get a weekly email update, and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication not affiliated with or endorsed by any other organization, society or journal referenced on the website. (Terms of Use | Privacy Policy)

Authors: contribute your work in a guest post.


What’s the best long-term anticoagulation Rx after a stent for people needing warfarin?